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Probiotics, live microorganisms that beneficially affect the health of their host, must 
undergo extensive research to ensure they are safe for consumption and possess certain 
functional properties. Antibiotic resistance in probiotics has raised concern due to the 
possibility of its transfer to pathogens. Acid and bile tolerance ensures that organisms 
will survive passage into the intestines. Prebiotic utilization indicates ability to ferment 
specific carbohydrates for enhanced growth.  The objective of this study was to 
characterize a group of commercial probiotics for their suitability as probiotics.  
Nine commercial probiotic strains (7 Lactobacillus, 1 Lactococcus lactis, and 1 
Bifidobacterium longum) were evaluated. Two methods, disk diffusion and broth 
microdilution, were utilized to determine susceptibility to 9 antibiotics (ampicillin, 
chloramphenicol, clindamycin, erythromycin, gentamycin, kanamycin, oxytetracycline, 
streptomycin, and vancomycin). Most strains were susceptible to 4 or more antibiotics. 
Only one strain, Lactobacillus salivarius, showed resistance to three antibiotics. The two 
methods tested were in agreement for 76.8% (63/82) of the bacteria-antibiotic 
combinations tested.  
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The cultures were assessed for their ability to utilize four prebiotics:  
galactooligosaccharides (GOS), two fructooligosaccharide (FOS), and inulin. Glucose 
was used as a positive control for growth. Galactooligosaccharides were fermented by 
seven strains and fructooligosaccharides derived from chicory, by two strains. Inulin did 
not promote significant growth of any of the strains. 
Additionally, Bacillus coagulans ProDura is a sporeforming bacterium that has recently 
been identified and marketed as a novel probiotic with a greater ability to survive the low 
pH of the stomach when in spore form. This organism showed high tolerance to acid and 
bile conditions, with only a two log reduction after four hours at pH 2.0, and only a one 
log reduction in bile salts. It was susceptible to all antibiotics tested and was able to 
utilize GOS and FOS, but not inulin.  In conclusion, the strains evaluated comply with the 
functional and safety characteristics of probiotics, except for the strain of Lactobacillus 
salivarius which demonstrated an unacceptable level of antibiotic resistance.  
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CHAPTER 1 : LITERATURE REVIEW 
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1.1. Lactic acid bacteria 
Lactic acid bacteria (LAB) are a group of Gram-positive bacteria that excrete lactic acid 
as their main fermentation product (1). Typical LAB members are Gram-positive, 
facultative anaerobic, catalase-negative organisms with low G+C content, of the genera 
Lactobacillus, Lactococcus, Leuconostoc and Pediococcus. Though the genera 
Propionobacterium and Bifidobacterium belong to the high G+C branch, they have been 
grouped with the LAB for practical and ecological reasons (2). 
 
Most LAB have a long history of being consumed as part of traditional fermented foods 
and have been awarded the status of “Generally Regarded As Safe” (GRAS) by the Food 
and Drug Administration (FDA) (2). Lactobacilli are naturally present or deliberately 
added as starter cultures in unpasteurized milk and dairy products such as cheeses, 
yogurts and fermented milks (3). Leuconostoc, Lactobacillus and Pediococcus species are 
commonly established in plant material and are essential for the manufacture of 
fermented vegetable products (e.g. miso, soy sauce, pickled vegetables and kimchi) (4). 
LAB starters are also used in dry sausage, where they affect the texture, flavor, shelf-life 
and safety of the product (5). 
 
1.2. Probiotics 
Probiotics are defined as cultures of living microorganisms which beneficially affect the 
health of the host when administered in adequate amounts (2). These microorganisms 
survive passage through the gastrointestinal tract and eventually establish in the colon. 
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However, they must be taken regularly and at sufficiently high levels to avoid washout 
and to ensure sustained benefits (4). Their benefits are related to the prevention of growth 
of harmful bacteria by competitive exclusion and by the production of organic 
compounds (5). Associated effects of probiotics include prevention and treatment of 
diarrhea, alleviation of lactose intolerance, immunomodulation and prevention or 
alleviation of allergies in children (4, 5). 
 
Global sales of probiotic products reached US$21.6 billion in 2010 and US$24.23 billion 
in 2011 (6). The global probiotic market is expected to reach US$44.9 billion in 2018 (6). 
Asia-Pacific is currently the largest probiotic market and is likely to remain the market 
leader; however, European and North American markets continue to grow (6). In the 
United States, probiotics are available primarily as capsules or sachet preparations, 
although food formats are increasing. Unlike Canada and some European countries, the 
United States has no governmental standards for probiotics, which leads to variable 
products that do not contain the bacteria or the number of bacteria stated in the product’s 
label (7). Consumer education and clearer regulations are needed for the probiotic market 
to reach its full potential in the United States. 
 
1.3. Bacterial species used as probiotics 
Lactic acid bacteria are normal residents of the human gastrointestinal tract, especially in 
the colon, where their numbers can be up to 9 log CFU/g (5). The two genera most 
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commonly used as probiotics are Lactobacillus and Bifidobacterium. Neither genera 
includes any significant pathogenic species (8). 
  
In healthy humans, lactobacilli are normally present in the oral cavity (103-104 CFU/g), 
the ileum (103-107 CFU/g), and the colon (104-108 CFU/g) (9). They are also widely 
found in raw milk and fermented dairy products, which continue to be the preferred way 
to market probiotic strains in food products in the United States (7). Beneficial effects of 
lactobacilli include control of intestinal inflammation, treatment of infections during 
pregnancy, management of allergic diseases, control of antibiotic-related diarrhea and 
prevention of urinary tract infections, amongst others (9). 
 
Bifidobacterium are not considered true LAB, given their high G+C content and their 
production of a combination of lactic and acetic acid. However, they are normal 
inhabitants of the gastrointestinal tract of humans, making up to 25% of the cultivable 
fecal bacteria in adults and 80% in infants (8).  They are commonly used as probiotics, 
with a long history of safe use in fermented dairy products. Their positive effects on 
human health include prevention of infection by pathogenic bacteria, immunostimulatory 
and anti-carcinogenic capabilities, protection against infectious diarrhea, lowering of 
serum cholesterol and alleviation of lactose intolerance (10). 
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Spore forming bacteria, such as Bacillus coagulans, Bacillus racemilacticus and Bacillus 
laevolacticus, have only recently received attention as potential probiotics. However, 
many factors make them good candidates for probiotic use, such as the ease of culturing 
them in bulk, their production of organic acids and their capacity to sporulate (11). 
Spores are hardy dormant life forms. One of their most important traits is that they are 
heat stable, so they can be included in products stored at room temperature without losing 
viability (12). Both in vitro and mouse model experiments have shown that Bacillus 
coagulans spores are capable of germinating in the small intestine, where they could 
arguably have a beneficial effect (13, 14). Certain strains of Bacillus coagulans are 
capable of producing a bacteriocin-like inhibitory substance, coagulin, which has shown 
in vitro activity against Enterococcus and Listeria (15). Mice studies have shown 
Bacillus coagulans consumption improves some indices of Clostridium difficile-induced 
colitis (16). Human trials suggest a certain strain of this species may have positive effects 
on functional intestinal gas symptoms and rheumatoid arthritis symptoms (17, 18). 
However, there are still very few human studies on the effects of Bacillus probiotics for 
them to achieve the same level of acceptance as lactobacilli and Bifidobacterium 
probiotics.  
 
1.4. Properties of probiotics 
The Food and Agriculture Organization (FAO) and the World Health Organization 
(WHO) released a joint report in 2002 for the evaluation of probiotics. To be classified as 
probiotics, strains must be identified by phenotypic and genotypic methods, since many 
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probiotic effects are strain-specific. Then, they should go through a functional 
characterization and a safety assessment, both in vitro and with animal studies, before 
being tested for efficacy in a double blind, randomized, placebo-controlled human trial 
(19). A second independent trial is preferred before the strain can be considered a 
probiotic and be added to food products. 
 
1.4.1. Functional properties of probiotics 
The beneficial effects of probiotics depend on their colonization of the gut and their 
effect on harmful bacteria, for which certain functional properties are necessary. 
Probiotics must survive gastric and bile acids in order to reach the intestinal tract (11). 
Once there, they must be capable of adhering to human epithelial cells. Lastly, they 
should prevent colonization by pathogenic bacteria, either by immune exclusion, 
competitive adhesion or synthesis of antimicrobial substances (13, 19). 
 
1.4.1.1. Acid and bile resistance 
Probiotic strain selection can start with screening for acid and bile resistance. The pH of 
excreted hydrochloric acid in the stomach is 0.9. However, the presence of food raises the 
pH value to around pH 3 (5). The ability to survive and grow in a low pH environment is 
characteristic of LAB, although their tolerance mechanism is not clarified yet. (20)  Bile 
salts, on the other hand, are released into the small intestine after ingestion of fatty foods. 
They have a detergent-like function, which may disrupt the lipids and fatty acids of 
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bacterial cell membranes (21). Certain microorganisms, including several species of 
Lactobacillus, can reduce this detergent effect by hydrolyzing bile salts with the bile salt 
hydrolase (BSH) enzyme (5, 20). 
 
In vivo methods are available for investigating the survival of probiotic bacteria in the 
human gut. As these methods are expensive, laborious and pose ethical constraints, in 
vitro methods are preferred for the first selection of strains (14). In these in vitro 
methods, cultures are usually exposed to acid conditions (pH 2 to 3) or bile presence 
(0.3% w/v) in broth for up to four hours. Growth or survival is then monitored (21). 
 
Bacillus species generate dormant spores resistant to heat, desiccation, enzymatic 
degradation and acidic conditions (22). This increases their potential as probiotics for 
human or animal use. In vitro experiments have shown that spores from different strains 
of Bacillus coagulans, Bacillus laevolacticus and Sporolactobacillus are able to tolerate 
pH conditions as low as 2.0 to a varying degree, according to strain and environment 
conditions (11, 14, 22–24). Similar tests have been performed for bile resistance, with 
only a slight loss of viability for most strains of Bacillus tested (11, 14, 22). Germination 
of Bacillus subtilis spores in the intestine of mice has been reported (25), which is 
necessary as only the vegetative cells are able to have a probiotic effect. 
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1.4.1.2. Prebiotic utilization 
Prebiotics are defined as  non-digestible food ingredients that beneficially affect the host 
by selectively stimulating the growth and/or the activity of one or a limited number of 
bacteria in the colon that have the potential to improve host health (8, 10). This is based 
on the knowledge that the availability of carbohydrates that escape metabolism and 
adsorption in the small intestine has a major influence on the microflora that becomes 
established in the colon (26). The main prebiotics used are carbohydrates such as resistant 
starch, wheat bran, inulin or oligosaccharides (27). 
 
Inulin is a natural component of several fruits and vegetables. It is a mixture of 
fructooligosaccharides and fructopolysaccharides (28).  Oligosaccharides are short 
polymers of glycosidic residues such as fructose in fructooligosaccharides (FOS) or 
galactose in galactooligosaccharides (GOS) (27). FOS is the most commonly used 
commercial prebiotic, which is a mixture of oligosaccharides containing a varying 
number of fructose moieties connected by β(2→1) glycosidic bonds. GOS originates 
from enzymatic transgalactosylation of lactose (10). These soluble and fermentable fibers 
cannot be digested by α-amylase or other hydrolases in the upper section of the intestinal 
tract and they also resist digestion by gastric acid and pancreatic enzymes (29).  
 
To exert a prebiotic effect, fibers have to be present in foods in amounts of 30-60 mg/g in 
solid foods and 15 mg/g in liquid foods (30). The effect will also depend on the actual 
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number of beneficial bacteria, such as bifidobacteria, in the host, which has led to 
development of products that combine both a probiotic and a prebiotic (28). Prebiotics by 
themselves as well as their symbiotic combination with probiotic bacteria have been 
shown to increase bifidobacteria and lactobacilli populations and to inhibit various 
human and animal pathogenic bacteria in vitro, or in mice, piglets or humans (28). The 
addition of prebiotics to products containing probiotics can also protect and stimulate 
growth of lactobacilli and bifidobacteria during the product’s shelf life (31, 32). 
However, it is important to determine whether the probiotic strain is capable of 
metabolizing the prebiotic. 
 
1.4.2. Safety properties of probiotics 
There has always been a level of concern about the safe use of lactic acid bacteria as 
probiotics. The following safety criteria have been proposed: strains intended for human 
use should have a human origin and be isolated from healthy human gastrointestinal tract 
and they need to have a non-pathogenic history, not associated with diseases (33). Now, 
it is considered necessary to also establish the absence of transmissible antibiotic 
resistance genes.  
 
1.4.2.1. Antibiotic resistance 
According to the WHO (34), antimicrobial resistance (AMR) is “the resistance of a 
microorganism to an antimicrobial medicine to which it was originally sensitive”. The 
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genes that code for resistance are components of natural microbial populations and the 
exposure to antibiotics exerts a selective pressure, favoring the microorganisms capable 
of surviving (35). Humans encourage the spread of resistant strains by the misuse of 
microbial medicines and by poor infection control practices (34). 
 
Awareness of this fact has encouraged major official bodies, such as the European Union 
(EU), the Centers for Disease Control and Prevention (CDC) and the WHO, to address 
the need of controlling the increase in resistance (36). Most agencies agree that a global 
strategy is needed and that it should include comprehensive surveillance of antibiotic 
resistant organisms and their associated infections; improved control and monitoring of 
antibiotic use in animals and humans; and increased research in the area of resistance 
mechanism identification and antibacterial drug product development (34, 37, 38). 
 
Antimicrobial susceptibility testing allows the detection of possible drug resistance in 
common pathogens and commensals and to identify the most appropriate drug treatment 
for patients (39). Conventional phenotypic methods are based on the assessment of the 
growth of bacteria when exposed to the antimicrobial of interest. The results are then 
compared to interpretative criteria provided by responsible organizations, such as the 
Clinical and Laboratory Standards Institute (CLSI; formerly the National Committee for 
Clinical Laboratory Standards, or NCCLS) in the United States and the European Union 
Committee for Antimicrobial Susceptibility Testing (EUCAST) in Europe (40).The most 
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commonly used methods are broth dilution tests, antimicrobial gradient methods and the 
disk diffusion test  (39). 
 
The known mechanisms of antibiotic resistance can be broadly classified into four 
classes: 1) lack or decrease of cell wall permeability, which limits or prevents the intake 
of the drug; 2) efflux mechanisms, which allow the bacteria to pump out the antibiotic 
from the cell before it reaches an effective concentration; 3) enzymatic deactivation 
mechanisms, in which inactivating enzymes alter the antibiotic’s chemical structure to 
render it useless; and 4) modification of target mechanisms, in which the target site of the 
antibiotic has been altered so it retains its function in the cell but the antibiotic can no 
longer bind to it (41). Certain mechanisms, such as lack of cell wall permeability or the 
total absence of the target site, are more likely to be inherent to a bacterial species or 
genus; therefore this type of resistance is classified as intrinsic or natural (Figure 1.1).  
However, strains belonging to a group naturally susceptible to an antibiotic can acquire 
resistance through gain of exogenous DNA or by mutation of indigenous genes (42). 
 Figure 1.1 Major mechanisms of intrinsic and acquired resistance (42)
 
Both intrinsic resistance and acquired resistanc
risk of horizontal dissemination between different bacterial species. In contrast, acquired 
resistance has a higher potential for transference when the genes are present on mobile 
genetic elements, such as plasmids and transposons
elements move between diverse bacteria and disseminate resistance genes into a variety 
of microbial communities 
 
1.4.2.2. Antibiotic resistance in LAB
Researchers in the last decade have discovered the presence of antibiotic resistance genes 
in LAB from different sources. Herreros 
LAB isolated from Armada cheese, a Spanish goat milk cheese. Masco 
. 
e by chromosomal mutation ha
 (43). Determinants on these mobile 
(35) 
 
et al. (44) found multiple drug resistance in 
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ve a low 
et al. (45) 
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discovered tet(W) genes responsible for tetracycline resistance in 15 Bifidobacterium 
strains, including 7 probiotic isolates. Surveys of antibiotic resistance phenotypes and 
determinants have been conducted with lactic acid bacteria strains of European, African 
and Asian origin and resistance genes have been found in all of them (46–49). There is 
very little published information about American strains.  
 
However, it is important to distinguish between intrinsic and acquired resistance. For 
example, enterococci are intrinsically resistant to cephalosporins and low levels of 
aminoglycosides; while lactobacilli, pediococci and Leuconostoc spp. have a high natural 
resistance to vancomycin (1). There are both intergenus and interspecies differences. 
Danielsen and Wind (50) surveyed 62 strains of Lactobacillus and found that 
susceptibility varied several folds between species for drugs such as vancomycin, 
tetracycline and clindamycin. These results emphasize the importance of surveillance and 
publication of resistance profiles of LAB and other commensal bacteria of industry 
interest for the development of safety guidelines for their commercial use.  
 
The European Food Safety Authority (EFSA), for example, took published data about 
resistance profiles into account for the development of its safety assessment scheme 
(Figure 1.2). This assessment must be done for all strains aiming to be used as additives 
in the European Union and represents a complete framework for the characterization of 
resistance of any microorganism (42).  
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Figure 1.2 EFSA proposed scheme for antimicrobial resistance assessment of a bacterial 
strain used as feed or food additive (42). 
 
In this proposed scheme, cut-off values are set by studying the distribution of minimum 
inhibitory concentrations (MICs) of the antimicrobials in bacterial populations of the 
same species or genus (42). Data about the distribution of MICs is derived from the 
published body of research and monitoring programs and may be updated as more 
information becomes available (51). Therefore, resistant strains are those for which MICs 
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clearly deviate from those of normal susceptible populations. EFSA recognizes nine 
antibiotics as antimicrobials of human and veterinary importance; susceptibility to these 
substances is considered a basic requirement for bacterial products intended for use as 
food and feed additives (Table 1.1) (51). 
 
Table 1.1 Antibiotics recognized as having human and veterinary importance by EFSA 
(51). 
Mechanism of action Antibiotic Family Antibiotics of Importance 
Inhibition of cell wall 
synthesis 
Penicillins Ampicillin 
Glycopeptides Vancomycin 
Inhibition of protein 
synthesis 
Aminoglycosides Gentamycin 
Kanamycin 
Streptomycin 
Macrolides Erythromycin 
Lincosamides Clindamycin 
Tetracyclines Tetracycline 
Single antibiotics Chloramphenicol 
 
The characterization of potentially probiotic strains is a comprehensive process. Beyond 
health properties, safety and functionality are also important. The bacteria should be able 
to survive processing, storage and digestion conditions. Acid and bile resistance is 
essential for its delivery to the small intestine, where it can exert its positive effect. 
Prebiotic utilization allows for the formulation of synbiotic products that can protect 
bacteria during the product’s shelf life and increase their activity in the intestinal tract. 
Most importantly, probiotic strains should be safe for human consumption and inclusion 
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in the food chain. The definition of a safe strain has expanded to include the absence of 
antibiotic resistance genes, given the alarming increase of resistance in pathogenic and 
commensal bacteria worldwide.  
 
Both safety and functional characteristics can be specific to a certain species or a certain 
strain of LAB. This makes it necessary to characterize each new strain intended for 
probiotic use, especially emerging species like Bacillus coagulans. Therefore, the current 
research focused on characterizing the functional and safety properties of ten probiotic 
strains, aiming to determine their ability to utilize prebiotics and their antibiotic 
resistance. This will contribute to their proper use in the food industry and to the general 
knowledge about these species. 
 
• ObjectivesTo characterize the prebiotic utilization profile of ten probiotic strains in 
order to suggest potential synbiotic combinations. 
• To evaluate the antibiotic susceptibility of ten probiotic strains, by both the broth 
microdilution and the disk diffusion method, to determine the safety of the strains 
and compare the performance of both methods. 
• To determine the in vitro acid and bile tolerance of Bacillus coagulans to predict 
its survival in the gastrointestinal tract. 
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CHAPTER 2 : MATERIALS AND METHODS 
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2.1. Probiotic strains 
Ten bacterial strains were obtained from a commercial probiotics supplier (Nebraska 
Cultures, Walnut Creek, CA) (Table 2.1). Control strains were purchased from the 
American Type Culture Collection (ATCC, Manassas, VA). The freeze-dried cultures 
were diluted 1:99 in Phosphate Buffered Saline (PBS; Sigma, St. Louis, MO) and 5 µl 
were streaked in appropriate media. Tryptic Soy Agar (TSA, Acumedia, Neogen 
Corporation, Lansing, MI) was used for Escherichia coli ATCC 25299 and Streptococcus 
pneumoniae ATCC 49619. De Man Rogosa Sharpe agar (MRS, Acumedia, Neogen 
Corporation, Lansing, MI) was used for all Lactobacillus, Lactococcus, Bifidobacterium 
and Bacillus. Plates were then incubated for 24 hours at 37°C. Plates were incubated 
anaerobically with the exception of E. coli ATCC 25922 and S. pneumoniae ATCC 
49619.  Single colonies were picked and a Gram stain was performed. Colonies with the 
expected morphology were grown overnight at 37°C, either in Tryptic Soy Broth (TSB, 
Acumedia, Neogen Corporation, Lansing, MI) or MRS broth (Acumedia, Neogen 
Corporation, Lansing, MI). Sterile glycerol at 7% (v/v) was added to the cultured broth 
and 1-ml aliquots were stored at -80°C. Isolates were then sent for identification by 16s 
sequencing (Midi Labs, Newark, DE). 
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Table 2.1 Bacterial strains used. 
Probiotic strains Control strains 
Lactobacillus acidophilus DDS 1-10 
Lactobacillus brevis 
Lactobacillus delbrueckii subsp. bulgaricus 
Lactobacillus casei 
Lactobacillus plantarum 
Lactobacillus rhamnosus 
Lactobacillus salivarius 
Lactococcus lactis 
Bifidobacterium longum 
Bacillus coagulans ProDURA 
Escherichia coli ATCC 25922 
Streptococcus pneumoniae ATCC 49619 
 
2.2. Prebiotic utilization by lactic acid bacteria 
Probiotic bacterial cultures were prepared by streaking 10 µL of stock culture into MRS 
plates and incubating overnight at 37°C. A single colony was then picked and transferred 
to 12 mL of MRS broth and incubated overnight at 37°C. For this assay, only 
Bifidobacteria were incubated anaerobically, in both plates and tubes. 
 
MRS broth without any sugar (basal MRS) was prepared and autoclaved. Sugar solutions 
were prepared, sterilized through a syringe filter (mixed cellulose ester membrane, 0.22 
µm pore size, Fisherbrand, Fisher Scientific, Waltham, MA) and added to the sterile 
medium to achieve the desired concentration (Table 2.2). Prebiotics used included two 
fructooligosaccharide mixtures from different suppliers (FOS, Nutraflora, GTC Nutrition 
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Company, Bridgewater, NJ and Orafti P95, Beneo, Manheim, Germany), one 
galactooligosaccharide  mixture (GOS, Purimune, GTC Nutrition Company, Bridgewater, 
NJ), and one inulin mixture (Orafti Synergy 1, Beneo, Manheim, Germany). Since all of 
these prebiotics contain residual simple sugars, a background sugar (bg) control was 
prepared for each one of them. Glucose was used as a positive control. Glucose and the 
prebiotic sugars were added to the media for a final concentration of 1% (w/v). 
 
MRS solutions were dispensed into sterile tubes and inoculated with the bacterial cultures 
at a 5% (v/v). Absorbance at 620 nm was read every two hours using a Biomate 3 
spectrophotometer (Thermo Scientific, Thermo Fisher Scientific, Waltham, MA). The 
corresponding sterile MRS solutions were used as blanks for absorbance measurements. 
The aliquot removed for absorbance measurements was diluted with the corresponding 
sterile MRS solution when absorbance was higher than 0.500. Growth curves were 
prepared from the absorbance measurements. Doubling time during the exponential phase 
was determined, as well as the maximal variation of absorbance (Figure 2.1). Doubling 
time was defined as the time needed for absorbance to double during the exponential 
phase of growth, as observed in the growth curves. Maximal variation of absorbance was 
calculated by subtracting the initial absorbance from the highest observed absorbance. 
The experiments were performed in triplicate. 
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Table 2.2 Sugar and prebiotic concentrations tested. 
Treatment Sugars Final concentration (%, w/v) 
Positive control Glucose 1.0% 
Orafti P95 
Fructooligosaccharide 
(FOS) 
Mixture of FOS (93%), 
glucose, fructose and 
sucrose 
0.93% FOS 
0.0175% glucose 
0.0175% fructose 
0.035% sucrose 
Orafti FOS background 
sugars (bg) 
Mixture of glucose, 
fructose and sucrose 
0.0175% glucose 
0.0175% fructose 
0.035% sucrose 
Nutraflora FOS Mixture of FOS (95%), 
glucose, fructose and 
sucrose 
0.95% FOS 
0.0125% glucose 
0.0125% fructose 
0.025% sucrose 
Nutraflora FOS bg Mixture of glucose, 
fructose and sucrose  
0.0125% glucose 
0.0125% fructose 
0.025% sucrose 
Purimune 
Galactooligosaccharide 
(GOS) 
Mixture of GOS (93%) 
and lactose 
0.93% GOS 
0.07% lactose 
GOS bg Lactose 0.07% lactose 
Orafti Sinergy 1 Inulin Mixture of inulin (92%), 
glucose, fructose  and 
sucrose 
0.92% inulin 
0.02% glucose 
0.02% fructose 
0.04% sucrose 
Inulin bg Mixture of glucose, 
fructose and sucrose  
0.02% glucose 
0.02% fructose 
0.04% sucrose 
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Figure 2.1 Determination of doubling time (DT) and maximal variation of absorbance 
(MVA) from probiotic growth curves. 
 
2.3. Antibiotic resistance 
2.3.1. Broth microdilution method for antibiotic resistance 
The procedure for broth microdilution was adapted from the CLSI protocol for 
antimicrobial susceptibility testing (52). Antibiotic solutions were prepared in LAB 
susceptibility media (LSM, 9:1 Isosensitest broth: MRS broth, Oxoid, Acumedia). The 
following antibiotics were tested: ampicillin, chloramphenicol, clindamycin, 
erythromycin, gentamycin, kanamycin (Sigma Aldrich, St. Louis, MO), oxytetracycline 
(Acros Organics, Geel, Belgium), streptomycin (MP Biomedicals, Santa Ana, CA) and 
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vancomycin (Fisher Scientific, Waltham, MA). The range of concentrations tested varied 
for each antibiotic according to the microbiological breakpoints (bp) defined by EFSA 
(51).  
 
Cultures for inoculation were grown overnight by mixing 100 µL of stock culture into 9 
mL of MRS broth and incubating anaerobically at 37°C overnight. Control strains were 
grown in TSB broth and incubated aerobically. The absorbance of culture tubes was then 
adjusted to 0.125-0.132 at 620 nm, the equivalent to a 0.5 McFarland standard (5 x 105 
CFU/ml). Absorbance was measured with a Spectronic 20D+ spectrophotometer 
(Spectronic Instruments, Thermo Fisher Scientific, Waltham, MA), using MRS broth as a 
blank. The antibiotic solutions were used to prepare a 1:200 dilution of bacteria 
inoculum. 
 
The mixture of antibiotic solution and inoculum was dispensed into a 96-well plate, with 
300 µL per well. Absorbance at 600 nm was measured with iMark Micro Plate Reader 
(Bio-Rad, Hercules, CA) at 0, 24 and 48 hours of incubation at 37°C. E. coli and S. 
pneumoniae controls were incubated aerobically at 37°C. Growth curves were prepared 
so that growth at the breakpoint could be compared with growth of the positive control to 
examine susceptibility. For this experiment, it was considered that absorbance of 0.200 or 
greater corresponds with growth visible to the naked eye. The experiments were 
performed in triplicate. 
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2.3.2. Disk diffusion method 
The disk diffusion method was a modification of the agar overlay method documented by 
Charteris et al. (53). Plates with 15 ml of MRS agar were overlaid with 4 ml of soft agar 
containing 200 µL of active culture, prepared as described for the broth microdilution 
assays. Antibiotic disks (Becton Dickinson, BD, Franklin Lakes, NJ) with the following 
amounts of the active compound were placed into the dry plates: ampicillin (10 µg), 
chloramphenicol (30 µg), clindamycin (2 µg), erythromycin (15 µg), gentamycin (10 µg), 
kanamycin (30 µg), oxytetracycline (30 µg), streptomycin (10 µg), and vancomycin (30 
µg). Plates were then incubated anaerobically at 37°C for 24 h. E. coli and S. pneumoniae 
controls were incubated aerobically at 37°C. Inhibition zone diameters were measured 
with a colony counter (Flash and Go, IUL Instruments, Neutec Group Inc, Farmingdale, 
NY) and interpreted according to the guidelines provided by Charteris et al. (53). Strains 
were classified as susceptible or resistant. The experiments were performed in triplicate. 
 
2.4. Acid and bile tolerance of Bacillus coagulans 
Freeze-dried spores of Bacillus coagulans (about 2.00 x 1011 CFU/g) were diluted in PBS 
to obtain a suspension with 1 x 108 spores/mL. To ensure only spores were present, spore 
suspensions were heat treated at 80°C for 12 minutes and then chilled in ice. The method 
for acid and bile resistance was modified from Hyronimus et al. (11). Tubes with 10 mL 
of MRS broth were adjusted to pH 2.0, 2.5 and 3.0 using 3.0 M hydrochloric acid (Sigma 
Aldrich, St. Louis, MO). MRS with 0.3% bile (Sigma Aldrich, St. Louis, MO) was also 
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prepared and 10 ml of the broth was dispensed into tubes. MRS broth without addition of 
acid or bile salts was used as a control. A 10 µL aliquot of the spore suspension was then 
added to each tube. Counts were performed by plating on MRS agar at times 0, 0.5, 1, 2, 
and 4h. Plates were incubated aerobically overnight at 37°C. Survival curves were 
prepared for each treatment and the area under the curve was compared to the control. 
Survival rates were also calculated, as the percent of the initial population that could be 
recovered after four hours (log CFU/ml at 4 h divided log CFU/ml at 0 h * 100%). The 
experiment was performed in triplicate. 
 
2.5. Statistical analysis 
Analysis of variance was used to evaluate the effect of different treatments in the acid 
and bile assay and in the prebiotic utilization assay. The analysis was conducted on the 
mean doubling time and maximal absorbance variation for the prebiotic growth curves 
and for the area under the curve for the acid and bile survival curves, with treatment as 
the independent variable. Statistical analysis was carried out using SAS 9.3 (SAS, Inc, 
Cary, NC). All tests were conducted at the 5% level of significance.  
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CHAPTER 3 : RESULTS AND DISCUSSION 
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3.1 Probiotic strain identification 
The identity of the probiotic strains was confirmed by 16s sequencing (MidiLabs, 
Newark, DE). The reports can be found in Appendix A. 
 
3.2 Prebiotic utilization by lactic acid bacteria  
The capacity of nine strains to use prebiotics as a carbon source was evaluated during 
growth for 24 hours. Glucose was used as a positive control for growth. The background 
sugars in each prebiotic were also evaluated, to establish their effect on growth and rule 
out their interference. The mean doubling time during the exponential phase of growth 
and the maximal absorbance variation were calculated for each strain and prebiotic. The 
results for lactobacilli (Lb.), Lactococcus lactis and Bifidobacterium longum (Bb. 
longum) are presented in Table 3.1 and Table 3.2. Figures 3.1 to 3.9 show the average of 
three replicates of the experiment for each strain. Results for Bacillus coagulans are 
included in its particular section. 
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Table 3.1 Mean doubling time of probiotic strains on selected carbohydrates.  
Mean Doubling Time (h, average ± standard deviation)1 
Treatment Lb. acidophilus Lb. brevis Lb. casei 
Glucose 1.5 ± 0.4 a 1.4 ± 0.3 a  1.1 ± 0.2 a 
Purimune GOS 1.8 ± 0.7 a 1.7 ± 0.4 a  1.6 ± 0.7 a 
Purimune GOS bg2 2.2 ± 0.9 a 2.0 ± 0.3 a  1.6 ± 0.6 a 
FOS Orafti 1.9 ± 0.6 a 1.6 ± 0.4 a  1.7 ± 0.6 a 
FOS Orafti bg 1.7 ± 0.5 a 1.7 ± 0.4 a  1.9 ± 0.9 a 
FOS Nutraflora 1.9 ± 0.5 a 1.9 ± 0.4 a  1.7 ± 0.7 a 
FOS Nutraflora bg 2.0 ± 0.3 a 1.9 ± 0.4 a  2.0 ± 1.1 a 
Inulin 1.9 ± 0.4 a 1.8 ± 0.3 a  1.8 ± 0.8 a 
Inulin bg 1.9 ± 0.4 a 1.8 ± 0.3 a  1.8 ± 0.8 a 
          
Treatment Lb. delbrueckii Lb. plantarum Lb. rhamnosus 
Glucose 1.6 ± 0.6 a 1.5 ± 0.5 a 1.1 ± 0.2 a 
Purimune GOS 1.5 ± 1.0 a 1.5 ± 0.4 a 1.6 ± 0.4 a,b 
Purimune GOS bg 1.8 ± 1.4 a 2.4 ± 0.6 a,b 2.9 ± 0.5 a,b,c 
FOS Orafti 1.8 ± 1.5 a 3.1 ± 0.8 a,b 3.1 ± 0.4 b,c 
FOS Orafti bg 1.7 ± 1.0 a 3.7 ± 0.8 b 4.4 ± 1.0 c 
FOS Nutraflora 1.5 ± 0.8 a 1.8 ± 0.5 a,b 3.4 ± 0.7 b,c 
FOS Nutraflora bg 1.6 ± 1.1 a 3.5 ± 0.9 a,b 3.2 ± 0.8 b,c 
Inulin 1.6 ± 1.1 a 2.8 ± 0.7 a,b 2.4 ± 0.4 a,b 
Inulin bg 1.7 ± 1.1 a 2.9 ± 0.6 a,b 3.1 ± 0.2 a,b,c 
          
Treatment Lb. salivarius L. lactis Bb. longum 
Glucose 2.2 ± 0.5 a 2.5 ± 0.7 a 1.9 ± 0.3 a 
Purimune GOS 2.4 ± 0.5 a 2.6 ± 0.9 a 3.7 ± 0.6 a,b,c 
Purimune GOS bg 4.4 ± 0.7 a,b,c 3.1 ± 1.0 a 3.3 ± 0.8 a,b,c 
FOS Orafti 5.6 ± 0.8 c 3.5 ± 0.9 a 2.9 ± 0.6 a,b,c 
FOS Orafti bg 5.0 ± 0.9 c 4.4 ± 1.0 a 4.4 ± 0.7 b,c 
FOS Nutraflora 2.8 ± 0.6 a,b 4.0 ± 1.1 a 4.5 ± 0.5 c 
FOS Nutraflora bg 5.7 ± 0.8 b,c 3.6 ± 1.0 a 2.9 ± 1.0 a,b,c 
Inulin 3.8 ± 0.8 a,b,c 3.3 ± 1.0 a 2.0 ± 0.6 a,b 
Inulin bg 4.6 ± 1.0 a,b,c 3.4 ± 0.6 a 4.0 ± 0.8 a,b,c 
1
 Mean doubling times with a different letter are significantly different (p<0.05) from 
doubling times for the same strain with other carbohydrates. 
2 bg: Background sugars. 
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Table 3.2 Maximal absorbance variation of probiotic strains on selected carbohydrates.  
Maximal absorbance variation (average ± standard deviation)1 
Treatment Lb. acidophilus Lb. brevis Lb. casei 
Glucose 0.28 ±0.12 a 1.97 ±0.30 a 1.81 ±0.03 a 
Purimune GOS 0.29 ±0.15 a 1.39 ±0.22 a,b 0.67 ±0.02 b 
Purimune GOS bg2 0.28 ±0.13 a 0.94 ±0.09 b 0.43 ±0.06 c 
FOS Orafti 0.21 ±0.03 a 1.06 ±0.13 b 0.34 ±0.09 c 
FOS Orafti bg 0.27 ±0.16 a 1.02 ±0.08 b 0.33 ±0.08 c 
FOS Nutraflora 0.28 ±0.12 a 0.98 ±0.21 b 0.30 ±0.08 c 
FOS Nutraflora bg 0.21 ±0.07 a 0.96 ±0.07 b 0.23 ±0.05 c 
Inulin 0.31 ±0.18 a 1.17 ±0.16 b 0.31 ±0.07 c 
Inulin bg 0.28 ±0.17 a 1.16 ±0.05 b 0.33 ±0.09 c 
          
Treatment Lb. delbrueckii Lb. plantarum Lb. rhamnosus 
Glucose 2.77 ±0.72 a 1.75 ±0.03 a 1.63 ±0.23 a 
Purimune GOS 2.23 ±0.51 a,b 1.49 ±0.03 b 1.14 ±0.17 b 
Purimune GOS bg 1.56 ±0.26 b 0.56 ±0.09 d 0.51 ±0.06 c 
FOS Orafti 1.28 ±0.19 b 0.45 ±0.02 d 0.40 ±0.03 c 
FOS Orafti bg 1.31 ±0.22 b 0.51 ±0.08 d 0.38 ±0.02 c 
FOS Nutraflora 1.69 ±0.37 a,b 0.94 ±0.07 c 0.38 ±0.06 c 
FOS Nutraflora bg 1.22 ±0.19 b 0.45 ±0.04 d 0.39 ±0.05 c 
Inulin 1.42 ±0.20 b 0.55 ±0.05 d 0.39 ±0.04 c 
Inulin bg 1.42 ±0.13 b 0.56 ±0.08 d 0.41 ±0.05 c 
          
Treatment Lb. salivarius L. lactis Bb. longum 
Glucose 2.15 ±0.25 a 0.59 ±0.12 a 2.19 ±0.00 a 
Purimune GOS 1.41 ±0.07 b 0.56 ±0.09 a,b 1.62 ±0.13 b 
Purimune GOS bg 0.58 ±0.07 d 0.29 ±0.04 c 0.38 ±0.06 c 
FOS Orafti 0.45 ±0.02 d 0.29 ±0.08 c 0.44 ±0.29 c 
FOS Orafti bg 0.46 ±0.06 d 0.30 ±0.07 b,c 0.40 ±0.07 c 
FOS Nutraflora 1.04 ±0.06 c 0.28 ±0.06 c 0.39 ±0.16 c 
FOS Nutraflora bg 0.53 ±0.07 d 0.29 ±0.08 b,c 0.28 ±0.11 c 
Inulin 0.65 ±0.09 d 0.30 ±0.08 b,c 0.46 ±0.08 c 
Inulin bg 0.54 ±0.02 d 0.31 ±0.07 b,c 0.49 ±0.13 c 
1
 Maximal absorbance variations with a different letter are significantly different (p<0.05) 
from maximal absorbance variations for the same bacteria with other carbohydrates. 
2 bg: Background sugars. 
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Figure 3.1 Growth of Lactobacillus acidophilus DDS 1-10 on selected carbohydrates. 
 
Figure 3.2 Growth of Lactobacillus brevis on selected carbohydrates. 
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Figure 3.3 Growth of Lactobacillus casei on selected carbohydrates. 
 
Figure 3.4 Growth of Lactobacillus delbrueckii on selected carbohydrates. 
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Figure 3.5 Growth of Lactobacillus plantarum on selected carbohydrates. 
 
Figure 3.6 Growth of Lactobacillus rhamnosus on selected carbohydrates. 
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Figure 3.7 Growth of Lactobacillus salivarius on selected carbohydrates. 
 
Figure 3.8 Growth of Lactococcus lactis on selected carbohydrates. 
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Figure 3.9 Growth of Bifidobacterium longum on selected carbohydrates. 
 
Mean doubling times with glucose ranged from 1.1 ± 0.2 hours for Lb. casei and Lb. 
rhamnosus to 2.5 ± 0.7 h for L. lactis. Mean doubling times were generally higher for 
glucose than for any other treatment for all bacteria; however, the difference between 
glucose and the rest of the treatments was not significant in most of the cases (p>0.05). 
This may be due to the high variability between replicates, as shown by the standard 
deviation. 
 
There was also no significant difference in doubling time between each prebiotic and its 
corresponding background sugars. This suggests that the strains utilized the available 
background sugars and residual glucose from inoculum during the beginning of the 
exponential phase, which allowed for mean doubling times similar to those of glucose. 
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Only after these sugars were exhausted would the strains be expected to begin utilizing 
the prebiotics.  
 
With the exception of Lb. acidophilus, all strains showed a higher absorbance increase 
for glucose than for the majority of background sugars, as shown in Figures 3.1 through 
3.9. This was expected, as glucose is the preferred carbon source for most 
microorganisms and similar results have been reported (54, 55). The lack of differences 
for Lb. acidophilus may be due to the low levels of growth achieved during the 
experiment. It is possible that different results could be obtained when incubating 
anaerobically. GOS use by this species has been reported under anaerobic conditions (54, 
56).  
 
Based on the maximal absorbance variation (Table 3.2), Purimune GOS was significantly 
utilized by Lb. casei, Lb. plantarum, Lb. rhamnosus, Lb. salivarius, L. lactis and Bb. 
longum, as the maximal absorbance increase was higher than the one for background 
sugars. However, it was not as high as the growth with glucose. Lb. casei showed a slight 
growth with GOS, enough to be different from the background sugars. This agrees with 
the results of Cardelle-Cobas et al. (56), who reported maximum optical densities of up to 
0.6 for Lb. casei with different galactooligosaccharides as the sole carbon source. In their 
study, the optical densities obtained with the GOS were similar to those achieved with 
lactose, which served as their positive control.  
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Lb. plantarum, Lb. rhamnosus, and Lb. salivarius were able to achieve significantly 
higher absorbance variations in GOS than in its background sugars. Cardelle-Cobas et al. 
(56) reported growth of Lb. plantarum and Lb. salivarius on GOS comparable to that 
achieved on lactose, their control sugar. L. lactis showed similar growth on glucose and 
GOS, which contrasts with the findings of Gopal et al. (57), who reported that none of 20 
Lactococci strains were able to grow on GOS. 
 
Lb. brevis and Lb. delbrueckii were not able to significantly utilize GOS, as there was no 
difference between GOS and its background sugars. Several studies have shown that the 
ability to ferment prebiotics is strain and substrate specific, due to differences in 
metabolic capacity of related strains (56). β-galactosidases are required for degradation of 
GOS into glucose and galactose (55). Lactobacilli express only intracellular β-
galactosidases and lack transport systems for GOS, which explains their usual preference 
for GOS with a low degree of polymerization so they can be internalized by lactose 
permeases such as LacS (55, 58). Therefore, utilization of prebiotics requires the 
presence of specific hydrolysis and transport systems for each prebiotic and the genes 
coding for these systems may not be present in the different strains (54). Genes encoding 
for LacS are highly conserved in intestinal lactobacilli, due to their importance for 
survival in the gastrointestinal tract (58). It is possible that the Lb. brevis and Lb. 
delbrueckii strains used in this study are non-intestinal in origin and therefore lack these 
genes. 
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Bb. longum was the only bacteria capable of achieving the same level of growth with 
GOS as with glucose. The ability of GOS to generate a beneficial shift in the colonic 
microbiota towards Bifidobacteria, known as a “bifidogenic effect”, has been widely 
reported in the literature (10, 59, 60). GOS was the only prebiotic to support growth of 
Bb. longum, as the rest were not significantly different from their corresponding 
background sugars. This agrees with previous studies using mixed flora samples, where 
the prebiotic index scores for GOS were higher than those for FOS and inulin (54).  
 
Orafti FOS did not promote significant growth of any of the tested strains. This contrasts 
with several reports in the literature of satisfactory growth of lactobacilli and 
bifidobacteria on this prebiotic (61, 62). However, Nutraflora FOS caused a significant 
increase in absorbance for Lb. plantarum and Lb. salivarius. Successful utilization of 
Nutraflora FOS by Lb. plantarum strains has been previously reported by Huebner et al. 
(54). They also reported differences in the increase in cell densities between lactobacilli 
when grown on either Nutraflora P95 FOS or Orafti Raftilose P95 FOS. The difference in 
utilization could be due to the higher number of fructose chains with a glucose end unit in 
cane sugar-derived Nutraflora FOS than in chicory root-derived Orafti FOS (63). 
 
Inulin did not promote significant growth of any of the strains tested. Inulin is a fructan 
of longer chain length than FOS, and non-digestible oligosaccharides of long chain length 
are less easily fermented by intestinal microbiota (64). Rossi et al. (65) reported that only 
38 
 
eight strains from a group of 55 Bifidobacterium strains were able to ferment inulin. 
Their strain set included two Bb. longum, from calf and human origin, which were not 
able to ferment inulin. The capacity to ferment inulin was linked to the presence of 
extracellular β-fructofuranosidase, the enzyme that hydrolyzes FOS and inulin (65). Van 
de Wiele et al. (64) also reported it took more time to observe significant effects from 
inulin than from FOS in the Simulator of Human Intestinal Microbial Ecosystem 
(SHIME). Therefore, it is possible that the strains studied lack the extracellular enzymes 
needed to hydrolyze FOS and inulin, or that assay time was not enough to observe the 
prebiotic effect of inulin. 
 
3.3 Antibiotic resistance 
The susceptibility profiles of ten probiotic strains were evaluated by both the broth 
microdilution method and the agar diffusion method. Results for the broth microdilution 
assay are presented in Table 3.3. Profiles from the disk diffusion method can be found in 
Table 3.4. Table 3.5 summarizes and compares the results for both methods. Of the 82 
bacteria-antibiotic combinations tested, 60 were classified as susceptible by both 
methods, while the other 12 were classified as resistant by either one or both methods. 
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Table 3.3 Antibiotic susceptibility profiles of strains by the broth microdilution method 
using EFSA susceptibility breakpoints. 
Antibiotic Bacteria MIC (mg/L) Breakpoint (mg/L) Classification 
Ampicillin Lb. acidophilus 1 - 2 1 Variable 
 Lb. brevis 2 2 Susceptible 
 Lb. casei 1 4 Susceptible 
 Lb. delbrueckii 1 1 Susceptible 
 Lb. plantarum 1 2 Susceptible 
 Lb. rhamnosus 1 4 Susceptible 
 Lb. salivarius 2 4 Susceptible 
 Bb. longum 1 2 Susceptible 
 L. lactis 1 2 Susceptible 
 B. coagulans n.r.1 n.r. n.r. 
Chloramphenicol Lb. acidophilus 4 4 Susceptible 
 Lb. brevis 4 4 Susceptible 
 Lb. casei 8 4 Resistant 
 Lb. delbrueckii 4 4 Susceptible 
 Lb. plantarum 8 8 Susceptible 
 Lb. rhamnosus 4 4 Susceptible 
 Lb. salivarius 4 4 Susceptible 
 Bb. longum 2 4 Susceptible 
 L. lactis 4 8 Susceptible 
 B. coagulans 2 8 Susceptible 
Clindamycin Lb. acidophilus 0.5 1 Susceptible 
 Lb. brevis >2 1 Resistant 
 Lb. casei >2 1 Resistant 
 Lb. delbrueckii 1 1 Susceptible 
 Lb. plantarum 1 2 Susceptible 
 Lb. rhamnosus 1 1 Susceptible 
 Lb. salivarius 0.5 1 Susceptible 
 Bb. longum >1 1 Resistant 
 L. lactis 4 1 Resistant 
 B. coagulans 4 4 Susceptible 
1
 n.r. not required by EFSA 
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Table 3. 3. Antibiotic susceptibility profiles of strains by the broth microdilution method 
using EFSA susceptibility breakpoints (continued). 
Antibiotic Bacteria MIC (mg/L) Breakpoint (mg/L) Classification 
Erythromycin Lb. acidophilus 0.5 1 Susceptible 
 Lb. brevis 1 1 Susceptible 
 Lb. casei 1 1 Susceptible 
 Lb. delbrueckii 2 1 Resistant 
 Lb. plantarum 0.5 1 Susceptible 
 Lb. rhamnosus 0.5 1 Susceptible 
 Lb. salivarius 0.5 1 Susceptible 
 Bb. longum 0.5 - >2 1 Variable 
 L. lactis 0.5 1 Susceptible 
 B. coagulans 1 4 Susceptible 
Gentamycin Lb. acidophilus 16 16 Susceptible 
 Lb. brevis 16 16 Susceptible 
 Lb. casei 16 32 Susceptible 
 Lb. delbrueckii 16 16 Susceptible 
 Lb. plantarum 16 16 Susceptible 
 Lb. rhamnosus 16 16 Susceptible 
 Lb. salivarius 32 16 Resistant 
 Bb. longum 16 64 Susceptible 
 L. lactis 16 32 Susceptible 
 B. coagulans 4 4 Susceptible 
Kanamycin Lb. acidophilus 64 64 Susceptible 
 Lb. brevis 32 32 Susceptible 
 Lb. casei 64 64 Susceptible 
 Lb. delbrueckii 16 16 Susceptible 
 Lb. plantarum 64 64 Susceptible 
 Lb. rhamnosus 64 64 Susceptible 
 Lb. salivarius >64 64 Resistant 
 Bb. longum n.r.1 n.r. n.r. 
 L. lactis 16 64 Susceptible 
 B. coagulans 8 8 Susceptible 
Oxytetracycline Lb. acidophilus 4 4 Susceptible 
 Lb. brevis 8 – 16  8 Variable 
 Lb. casei 4 4 Susceptible 
 Lb. delbrueckii 4 4 Susceptible 
 Lb. plantarum 32 32 Susceptible 
 Lb. rhamnosus 8 8 Susceptible 
 Lb. salivarius 4 8 Susceptible 
 Bb. longum 4 8 Susceptible 
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Table 3. 3. Antibiotic susceptibility profiles of probiotic strains by the broth microdilution 
method using EFSA susceptibility breakpoints (continued). 
Antibiotic Bacteria MIC (mg/L) Breakpoint (mg/L) Classification 
Oxytetracycline L. lactis 8 4 Resistant 
 B. coagulans 4 8 Susceptible 
Streptomycin Lb. acidophilus 16 16 Susceptible 
 Lb. brevis 16 64 Susceptible 
 Lb. casei 16 64 Susceptible 
 Lb. delbrueckii 16 16 Susceptible 
 Lb. plantarum n.r.1 n.r. n.r. 
 Lb. rhamnosus 32 32 Susceptible 
 Lb. salivarius >64 64 Resistant 
 Bb. longum 128 128 Susceptible 
 L. lactis 16 32 Susceptible 
 B. coagulans 8 8 Susceptible 
Vancomycin Lb. acidophilus 2 2 Susceptible 
 Lb. brevis n.r. n.r. n.r. 
 Lb. casei n.r. n.r. n.r. 
 Lb. delbrueckii 1 2 Susceptible 
 Lb. plantarum n.r. n.r. n.r. 
 Lb. rhamnosus n.r. n.r. n.r. 
 Lb. salivarius n.r. n.r. n.r. 
 Bb. longum 2 2 Susceptible 
 L. lactis 4 4 Susceptible 
 B. coagulans 1 4 Susceptible 
1
 n.r. not required by EFSA 
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Table 3.4 Antibiotic susceptibility profiles of strains by the disk diffusion method using 
susceptibility criteria established by Charteris et al.(53) 
Antibiotic Bacteria Inhibition diameter (mm, 
average ± standard 
deviation) 
Classification 
Ampicillin Lb. acidophilus 38 ± 0.2 Susceptible 
 Lb. brevis 29 ± 1.4 Susceptible 
Resistant ≤ 12 mm Lb. casei 36 ± 1.3 Susceptible 
Moderate 13-15 mm Lb. delbrueckii 38 ± 1.2 Susceptible 
Susceptible  ≥ 16 mm Lb. plantarum 45 ± 0.7 Susceptible 
 Lb. rhamnosus 38 ± 0.6 Susceptible 
 Lb. salivarius 32 ± 0.7 Susceptible 
 Bb. longum 39 ± 0.4 Susceptible 
 L. lactis 34 ± 2.4 Susceptible 
 B. coagulans n.r.1 n.r. 
Chloramphenicol Lb. acidophilus 36 ± 0.0 Susceptible 
 Lb. brevis 35 ± 1.8 Susceptible 
Resistant ≤ 13 mm Lb. casei 33 ± 0.7 Susceptible 
Moderate 14-17 mm Lb. delbrueckii 36 ± 1.3 Susceptible 
Susceptible  ≥ 18 mm Lb. plantarum 29 ± 0.5 Susceptible 
 Lb. rhamnosus 31 ± 4.0 Susceptible 
 Lb. salivarius 31 ± 0.2 Susceptible 
 Bb. longum 25 ± 0.4 Susceptible 
 L. lactis 30 ± 0.4 Susceptible 
 B. coagulans 39 ± 4.1 Susceptible 
Clindamycin Lb. acidophilus 18 ± 7.0 Susceptible 
 Lb. brevis 15 ± 1.5 Susceptible 
Resistant ≤ 8 mm Lb. casei 14 ± 0.8 Susceptible 
Moderate 9-11 mm Lb. delbrueckii 39 ± 2.0 Susceptible 
Susceptible  ≥ 12 mm Lb. plantarum 12 ± 2.4 Susceptible 
 Lb. rhamnosus 20 ± 0.0 Susceptible 
 Lb. salivarius 26 ± 3.6 Susceptible 
 Bb. longum 14 ± 2.1 Susceptible 
 L. lactis 22 ± 15.1 Susceptible 
 B. coagulans 43 ± 3.5 Susceptible 
1
 n.r. not required by EFSA 
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Table 3.4. Antibiotic susceptibility profiles of strains by the disk diffusion method using 
susceptibility criteria established by Charteris et al. (53) (continued). 
Antibiotic Bacteria Inhibition diameter (mm) Classification 
Erythromycin Lb. acidophilus 40 ± 1.2 Susceptible 
 Lb. brevis 35 ± 1.3 Susceptible 
Resistant ≤ 13 mm Lb. casei 40 ± 0.4 Susceptible 
Moderate 14-17 mm Lb. delbrueckii 39 ± 1.7 Susceptible 
Susceptible  ≥ 18 mm Lb. plantarum 29 ± 1.2 Susceptible 
 Lb. rhamnosus 40 ± 0.2 Susceptible 
 Lb. salivarius 30 ± 0.2 Susceptible 
 Bb. longum 39 ± 0.0 Susceptible 
 L. lactis 32 ± 1.1 Susceptible 
 B. coagulans 44 ± 4.1 Susceptible 
Gentamycin Lb. acidophilus 14 ± 0.3 Susceptible 
 Lb. brevis 16 ± 0.0 Susceptible 
Resistant ≤ 12 mm Lb. casei 15 ± 0.7 Susceptible 
Moderate  -  mm Lb. delbrueckii 19 ± 1.4 Susceptible 
Susceptible  ≥ 13 mm Lb. plantarum 16 ± 0.6 Susceptible 
 Lb. rhamnosus 16 ± 0.9 Susceptible 
 Lb. salivarius 9 ± 0.6 Resistant 
 Bb. longum 16 ± 0.1 Susceptible 
 L. lactis 20 ± 0.3 Susceptible 
 B. coagulans 31 ± 0.0 Susceptible 
Kanamycin Lb. acidophilus 7 ± 0.0 Resistant 
 Lb. brevis 7 ± 0.0 Resistant 
Resistant ≤ 13 mm Lb. casei 7 ± 0.0 Resistant 
Moderate 14-17 mm Lb. delbrueckii 22 ± 0.7 Susceptible 
Susceptible  ≥ 18 mm Lb. plantarum 7 ± 0.0 Resistant 
 Lb. rhamnosus 10 ± 0.6 Resistant 
 Lb. salivarius 7 ± 0.0 Resistant 
 Bb. longum n.r.1 n.r. 
 L. lactis 7 ± 0.0 Resistant 
 B. coagulans 30 ± 0.4 Susceptible 
1
 n.r. not required by EFSA 
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Table 3.4. Antibiotic susceptibility profiles of strains by the disk diffusion method using 
susceptibility criteria established by Charteris et al. (53) (continued). 
Antibiotic Bacteria Inhibition diameter (mm) Classification 
Tetracycline Lb. acidophilus 43 ± 0.9 Susceptible 
 Lb. brevis 28 ± 0.1 Susceptible 
Resistant ≤ 14 mm Lb. casei 39 ± 2.3 Susceptible 
Moderate 15-18 mm Lb. delbrueckii 37 ± 0.6 Susceptible 
Susceptible  ≥ 19 mm Lb. plantarum 23 ± 0.2 Susceptible 
 Lb. rhamnosus 28 ± 1.9 Susceptible 
 Lb. salivarius 24 ± 0.1 Susceptible 
 Bb. longum 30 ± 0.2 Susceptible 
 L. lactis 33 ± 0.2 Susceptible 
 B. coagulans 54 ± 4.8 Susceptible 
Streptomycin Lb. acidophilus 18 ± 0.3 Susceptible 
 Lb. brevis 7 ± 0.1 Resistant 
Resistant ≤ 11 mm Lb. casei 10 ± 0.1 Resistant 
Moderate 12-14 mm Lb. delbrueckii 22 ± 0.3 Susceptible 
Susceptible  ≥ 15 mm Lb. plantarum n.r. n.r. 
 Lb. rhamnosus 12 ± 0.5 Moderate 
 Lb. salivarius 7 ± 0.0 Resistant 
 Bb. longum 13 ± 0.8 Moderate 
 L. lactis 19 ± 1.0 Susceptible 
 B. coagulans 29 ± 1.2 Susceptible 
Vancomycin Lb. acidophilus 27 ± 0.4 Susceptible 
 Lb. brevis n.r.1 n.r. 
Resistant ≤ 14 mm Lb. casei n.r. n.r. 
Moderate 15-16 mm Lb. delbrueckii 28 ± 1.0 Susceptible 
Susceptible  ≥ 17 mm Lb. plantarum n.r. n.r. 
 Lb. rhamnosus n.r. n.r. 
 Lb. salivarius n.r. n.r. 
 Bb. longum 7 ± 0.0 Resistant 
 L. lactis 23 ± 0.2 Susceptible 
 B. coagulans 42 ± 4.6 Susceptible 
1
 n.r. not required by EFSA 
 
 
Table 3.5 Comparison of antibiotic susceptibility profiles of probiotic strains by the broth 
microdilution method and disk diffusion method. 
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Bacteria A
m
pi
ci
lli
n
 
Ch
lo
ra
m
ph
en
ic
o
l 
Cl
in
da
m
yc
in
 
Er
yt
hr
o
m
yc
in
 
G
en
ta
m
yc
in
 
K
an
am
yc
in
 
O
x
yt
et
ra
cy
cl
in
e 
St
re
pt
o
m
yc
in
 
V
an
co
m
yc
in
 
Lb. acidophilus V / S S / S S / S S / S S / S S / R S / S S / S S / S 
Lb. brevis S / S S / S R / S S / S S / S S / R V / S S / R n.r. 
Lb. casei S / S R / S R / S S / S S / S S / R S / S S / R n.r. 
Lb. delbrueckii S / S S / S S / S R / S S / S S / S S / S S / S S / S 
Lb. plantarum S / S S / S S / S S / S S / S S / R S / S n.r. n.r. 
Lb. rhamnosus S / S S / S S / S S / S S / S S / R S / S S/MS n.r. 
Lb. salivarius S / S S / S S / S S / S R / R R / R S / S R / R n.r. 
Bb. longum S / S S / S R / S V / S S / S n.r. S / S S/MS S / R 
L. lactis S / S S / S R / S S / S S / S S / R R / S S / S S / S 
B. coagulans n.r. S / S S / S S / S S / S S / S S / S S / S S / S 
R: Resistant, S: Susceptible, MS: Moderately Susceptible, V: Variable, N.R.: Not 
required. 
 
3.2.1 Lactobacilli strains 
Lactobacillus acidophilus was susceptible to all antibiotics by the broth microdilution 
method. However, it was classified as resistant to kanamycin by the disk diffusion 
method. Several studies have found that intrinsic resistance to kanamycin in the 
Lactobacillus acidophilus group is higher than initially described (50, 66). For example, 
Danielsen and Wind (50) suggested a breakpoint of >256 mg/L for kanamycin for all 
Lactobacillus species after testing 37 strains. The new distribution data prompted the 
European Food Safety Authority (EFSA) to change their regulatory limits accordingly, 
increasing the resistance breakpoint for this species from 16 mg/L in 2008 to 64 mg/L in 
2012 (42, 51). The MICs found for all antibiotics were comparable to those reported by 
46 
 
Mayrhofer et al. (66), who characterized the susceptibility of 101 strains belonging to the 
Lb. acidophilus group, including 10 strains of Lb. acidophilus. 
 
Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus brevis and 
Lactobacillus casei were also classified as resistant to kanamycin solely by the disk 
diffusion assay. The MIC for kanamycin for all strains coincided with the EFSA 
breakpoint. This suggests that the limits for the disk diffusion test might need to be 
reviewed for this antibiotic when testing Lactobacillus species. The cut-off values for the 
disk diffusion method were proposed by Charteris et al. in 1998 (53) and have been used 
in several studies since then (67–69). Mayrhofer et al. (70) recently compared the broth 
microdilution and agar disk diffusion methods for susceptibility testing of Lb. acidophilus 
group members, finding a strong correlation between MICs and inhibition zone diameters 
for several antibiotics. However, they did not establish guidelines for classification and 
their study did not include kanamycin. 
 
Lb. brevis and Lb. casei both had a similar susceptibility profile, as they were classified 
as resistant to streptomycin only by disk diffusion and as resistant to clindamycin only by 
broth microdilution. Lb. casei also exhibited resistance to chloramphenicol in the broth 
microdilution assay, while Lb. brevis showed variable susceptibility to tetracycline. Both 
organisms showed no inhibition zones in the disk diffusion assay for streptomycin; yet, 
their MIC was much lower than the EFSA breakpoint (16 mg/L vs 64 mg/L). 
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Streptomycin belongs to the aminoglycoside category of antibiotics, which also includes 
kanamycin. Increased MICs for aminoglycosides have been reported when using MRS 
agar for testing. MRS agar has a lower pH (6.2 ± 0.2) than the pH optimum for this group 
of antibiotics (pH 7.8) (71).  
 
Lb. casei or Lb. brevis resistance to clindamycin is rare in the available literature, only 
reported for one Lb. casei strain by Charteris et al. (53) and two Lb. brevis strains by 
Delgado et al. (72) and Herreros et al. (44). For chloramphenicol, D’Aimmo et al. (33) 
reported a MIC of 16 mg/L for 6 strains of Lb. casei, which is higher than the MIC found 
in this study (8 mg/L) and the EFSA breakpoint (4 mg/L). Resistance has also been 
reported for 10 out of 29 Lb. casei isolates from European probiotic products examined 
by the disk diffusion assay (73). Resistance to chloramphenicol, clindamycin or 
tetracycline is not intrinsic to lactobacilli; therefore, it would be important to study for the 
presence of known genes providing such resistance in these strains. 
 
Lactobacillus delbrueckii subsp. bulgaricus only showed resistance to erythromycin in 
the broth microdilution assay. It was classified as susceptible to all other antibiotics. The 
erythromycin resistance determinant erm(B) has been reported previously in different 
lactobacilli from different sources (46, 74–76). As an acquired resistance determinant, it 
can be potentially be transferred to other bacterial species, as shown by Nawaz et al. (76). 
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This raises a concern regarding the safety of this strain, making it necessary to screen for 
the presence of this resistance determinant. 
 
In contrast, Lactobacillus salivarius was the only strain to show clear resistance to more 
than one antibiotic in both assays. It was not susceptible to the three aminoglycosides: 
gentamycin, kanamycin and streptomycin. The MIC for kanamycin was >64 mg/L, the 
highest concentration tested. However, as discussed with Lb. acidophilus, Danielsen and 
Wind (50) have suggested a breakpoint of >256 mg/L for kanamycin for all Lactobacillus 
species after testing 37 strains. The MIC for streptomycin for L. salivarius was also >64 
mg/L, while the MIC for gentamycin was 32 mg/L. This is in agreement with previous 
reports of a lower MIC for gentamycin than for the rest of the aminoglycosides (50). The 
three aminoglycoside antibiotics act as inhibitors of protein synthesis (53). Lactobacilli 
show intrinsic resistance to this group of antibiotics due to cell wall structure and 
membrane impermeability, which may be complemented by efflux mechanisms (49). 
However, the presence of resistance determinants such as aac(6’)-aph(2’’) for gentamicin 
and kanamycin resistance and ant(6) and aphE for streptomycin resistance, has been 
reported in Lb. plantarum (49) and Bifidobacterium longum (75). Multidrug resistance is 
not common in lactobacilli, so presence of acquired resistance genes cannot be ruled out. 
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3.2.2 Other probiotic strains 
Lactococcus lactis was resistant to kanamycin (inhibition zone diameter = 7 mm) in the 
disk diffusion assay. This could be due to media interference, as previously discussed. 
Lactococci also have a high natural resistance to gentamicin and kanamycin (2). 
Additionally, it was classified as resistant to clindamycin (MIC = 4 mg/L) and 
oxytetracycline (MIC = 8 mg/L) by the broth microdilution method. Ammor et al. (75) 
characterized the MICs of 50 L. lactis strains for 6 antibiotics, including clindamycin and 
tetracycline. The MICs ranged from <0.032 to 0.5 mg/L for clindamycin and from 0.125 
to 0.5 mg/L for tetracycline. The incidence of resistance to antibiotics in lactococci is low 
in the literature; however, Rodriguez-Alonso et al. (77) did find lactococci strains 
resistant to tetracycline (n = 2) and clindamycin (n =1) during their survey of 46 
lactococci isolates from artisanal raw milk cheeses. As broth microdilution is considered 
the standard method for determining antibiotic resistance, it is recommended to look for 
genetic determinants for the observed resistance in this strain. 
 
 The only Bifidobacterium in the group, Bb. longum, exhibited a variable profile, with 
many differences among methods. It showed certain resistance to clindamycin and 
erythromycin in the broth microdilution assay and resistance to streptomycin and 
vancomycin in the disk diffusion method. Erythromycin is a member of the macrolide 
family of antibiotics, while clindamycin is part of the lincosamides. Resistance to both 
antibiotics in the same strain suggests a common resistance mechanism, which leads to 
the phenotype known as macrolide-lincosamide-streptogramin (MLS) phenotype (75). 
50 
 
This phenotype is due to the presence of erm genes encoding a 23S rRNA methylase that 
modifies the antibiotic’s target (78). Several classes of erm genes have been reported in a 
number of clinically important organisms, as well as in several lactic acid bacteria (73).  
 
Some bifidobacteria species are considered naturally resistant to aminoglycosides (2), 
which explains the lack of a MIC for kanamycin amongst the EFSA guidelines. 
Vancomycin resistant bifidobacteria were found by Charteris et al. (79) when using the 
disk diffusion method. However, most reports classify bifidobacteria species as 
susceptible to this antibiotic (2, 72). The discrepancy may be due to differences in assay 
methodology, since it has been suggested that vancomycin diffuses poorly in agar (79). 
Lastly, the variability observed for Bb. longum could be explained by the use of methods 
optimized for lactobacilli, which leads to occasional poor growth and low repeatability of 
results.  
 
3.2.3 Comparison of broth microdilution and disk diffusion methods 
The broth microdilution and disk diffusion methods were in agreement for 76.8% (63/82) 
of the bacteria-antibiotic combinations tested, as shown in Table 3.6. Both methods found 
similar numbers of resistant and susceptible bacteria. However, each method seems to 
have a slight bias. The broth microdilution classified four more bacteria as resistant to 
clindamycin than the disk diffusion method. The disk diffusion method classified six 
more bacteria as resistant to kanamycin than the broth microdilution method (Table 3.5).  
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Table 3.6 Comparison of broth microdilution and disk diffusion methods for bacteria-
antibiotic combinations tested. 
Method Resistant Susceptible Variable or Moderate Total 
Broth microdilution 10  69 3 82 
Disk diffusion 12  68 2 82 
Both methods 3 60 19 82 
 
As for precision of the methods, Mayrhofer et al. (70) suggests an acceptable 
repeatability of ±1 log base 2 for MICs and ± 3 to 4 mm for inhibition zone diameters for 
disk diffusion. All MICs determined were within this suggested range, while 5 inhibition 
zone diameters had a standard deviation higher than 4 millimeters. Interestingly, 3 of 
those diameters were related to Bacillus coagulans. This may be explained by the 
optimization of the disk diffusion method for lactobacilli species. The antibiotics with 
larger standard deviations for inhibition zone diameters were clindamycin (average 
standard deviation: 2.5 mm), erythromycin (average standard deviation 1.5 mm) and 
chloramphenicol (average standard deviation: 1.4 mm). This confirms the acceptable 
repeatability of the disk diffusion method, as well as the broth microdilution method. 
 
3.3 Properties of the potential probiotic strain Bacillus coagulans ProDura 
 
3.3.1 Acid and bile tolerance of Bacillus coagulans 
The in vitro tolerance of Bacillus coagulans to either acid or bile was assessed during a 
period of four hours. The average counts (log CFU/g) for each treatment are presented in 
Figure 3.10. Survival was compared against the control using the area under the curve 
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and survival rates (Table 3.7). Bacillus coagulans spores were able to survive all 
conditions tested, including pH 2.0. Survival ranged from 72.5 ± 3.3% in pH 2.0 to 91.9 
± 3.6% in 0.3% bile salts. Acidic conditions had a significant effect over survival, 
decreasing counts by at least 1 log cycle for all the pH values tested. As expected, 
reductions in counts were higher at the lower pH values.  
 
 
Figure 3.10 Bacillus coagulans cell survival in MRS broth with either acid or bile salts. 
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Table 3.7 Bacillus coagulans tolerance to acid and bile salts. 
Treatment 
Average area under the curve 
(log CFU/ml * h, ± SD)1 
Average survival 
(% , ± SD) 
Control 27.42 ± 0.30 a 99.5 ± 3.0 a 
pH 2.0 21.34 ± 0.90 c 72.5 ± 3.3 d 
pH 2.5 22.59 ± 0.56 b,c 79.4 ± 1.5 c,d 
pH 3.0 24.60 ± 1.31 b 86.6 ± 5.3 b,c 
Bile salts (0.3%) 26.72 ± 0.09 a 91.9 ± 3.6 a,b 
1Treatments with different letters within the same column are significantly different 
(p<0.05). 
 
 
Bacillus coagulans survival in low pH has been documented before. Sudha et al. (80) 
found a 2 log cycle reduction in B. coagulans Unique IS-2 spore counts after exposing 
the strain to pH 1.5 for 3 hours and a 1 log cycle reduction at pH 2.0 and 3.0. The strain 
studied here exhibited greater susceptibility to pH 2.0, with a predicted 2 log cycle 
reduction after 3 hours. Tolerance seems to vary amongst strains of B. coagulans, as 
Hyronimus et al. (11) tested 3 different strains (BCI4 LMAB, CIP5264 and CIP6625) and 
none of them showed detectable survival after 3 hours at pH 2.5. Those three strains were 
also weakly tolerant to 0.3% bile. B. coagulans Unique IS-2, on the other hand, had only 
a 1 log cycle reduction after 3 hours in 1.0% bile (80). Maathuis et al. (14) tested survival 
of B. coagulans GanedenBC30 during passage through a dynamic model of the stomach 
and small intestine (TIM-1) and found high survival (70%). 
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In vitro tolerance to acid and bile has been positively correlated to survival in both human 
and pig gastrointestinal tracts (81, 82). Guo et al. (81) screened Bacillus strains for 
probiotic characteristics, including acid and bile tolerance. B. subtilis MA 139 had 
constant counts during 3 hours at pH 2.0 and was capable of growing in mixed nutrient 
broth with 0.3% bile. It was also able to exert a probiotic effect in pigs. Succi et al. (83) 
found that the popular probiotic strain, Lactobacillus rhamnosus GG, showed reductions 
of 2 log cycles and 6 log cycles when exposed for 2 hours to pH 3.0 and pH 2.0, 
respectively. Survival in the gut is supposed to be higher thanks to the buffering effect of 
food products consumed at the same time as the probiotic. Bacillus coagulans strains 
show higher tolerance to acid than L. rhamnosus GG, so that their delivery to the lower 
intestinal tract is very promising. Their tolerance to acid would also make them suitable 
for addition to acidified foods, where they could arguably survive and remain viable.  
 
3.3.2 Prebiotic utilization by Bacillus coagulans 
The capacity of B. coagulans to use four commercial prebiotics as a carbon source was 
evaluated during growth for 24 hours. Glucose was used as a positive control for growth. 
The background sugars in each prebiotic were also evaluated, to establish their effect on 
growth and rule out their interference. The mean doubling time during the exponential 
phase of growth and the maximal absorbance variation were calculated for each prebiotic. 
Results are presented in Table 3.8 and Figure 3.11. 
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Mean doubling times ranged from 1.2 to 2.0 hours, but were not significantly different 
amongst all treatments. Based on maximal absorbance variation, B. coagulans grew well 
on media supplemented with glucose, as expected. It showed similar growth on media 
supplemented with GOS. Maximal absorbance variation was significantly higher for 
glucose and GOS, doubling the absorbance obtained with other treatments. It must be 
noted that the maximal absorbance variation (0.57 ± 0.02) is much lower than those 
observed with the other probiotic strains tested. This suggests that, while B. coagulans is 
capable of growing in the test conditions, these are not optimal for growth. 
 
Table 3.8 Prebiotic utilization by Bacillus coagulans. 
Treatment 
Mean doubling time (h, 
average ± standard deviation)1  
Maximal absorbance variation 
(average ± standard deviation)2 
Glucose 1.2 ± 0.0 a 0.57 ± 0.02 a 
Purimune GOS 1.4 ± 0.1 a 0.50 ± 0.07 a 
Purimune GOS bg3 1.7 ± 0.3 a 0.23 ± 0.05 b 
FOS Orafti 1.8 ± 0.3 a 0.14 ± 0.03 b 
FOS Orafti bg 1.8 ± 0.6 a 0.17 ± 0.06 b 
FOS Nutraflora 2.0 ± 0.6 a 0.16 ± 0.03 b 
FOS Nutraflora bg 1.7 ± 0.4 a 0.19 ± 0.04 b 
Inulin 1.4 ± 0.4 a 0.19 ± 0.03 b 
Inulin bg 1.9 ± 0.5 a 0.19 ± 0.07 b 
1
 Mean doubling times with a different letter are significantly different (p<0.05) from 
doubling times with other carbohydrates. 
2
 Maximal absorbance variations with a different letter are significantly different (p<0.05) 
from maximal absorbance variations with other carbohydrates. 
3 bg: Background sugars. 
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Figure 3.11 Growth of Bacillus coagulans on selected carbohydrates. 
 
There is little available information in the literature about in vitro use of prebiotics by B. 
coagulans or other Bacillus species. β-galactosidases from Bacillus circulans, B. 
coagulans and B. stearothermophilus have been widely studied for the production of 
GOS, since β-galactosidases are capable of catalyzing both the hydrolysis of β-
galactoside linkages of lactose to glucose and the transgalactosidation reaction to produce 
galactooligosaccharides (84–86). It has been reported that Bifidobacterium show greater 
growth on GOS produced by their own β-galactosidase than on commercial products 
(87). A similar behavior could be expected from Bacillus species and GOS. 
 
Based on the results, no difference in growth between FOS and its background sugars 
was found. However, there are several in vivo studies in different species of fish where 
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performance, survival and non-specific immune response when compared to each 
supplement by itself or to a control diet (88–90). This suggests a synbiotic relationship 
between the bacteria and the carbohydrate.  
 
B. coagulans was not able to ferment inulin as a carbohydrate source. This agrees with 
the results of De Clerck et al. (91) who performed the biochemical characterizations of 
31 strains of B. coagulans using the API tests, and found that none of them was capable 
of producing acid from inulin. 
 
3.3.3 Antibiotic susceptibility of Bacillus coagulans 
Antibiotic susceptibility of B. coagulans was determined by the broth microdilution 
method. Results are summarized in Table 3.9.  
 
Table 3.9 Antibiotic susceptibility profile of Bacillus coagulans by broth microdilution 
method using EFSA susceptibility criteria. 
Antibiotic MIC (mg/L) Breakpoint (mg/L) Classification 
Ampicillin n.r.1 n.r. n.r. 
Chloramphenicol 2 8 Susceptible 
Clindamycin 4 4 Susceptible 
Erythromycin 1 4 Susceptible 
Gentamycin 4 4 Susceptible 
Kanamycin 8 8 Susceptible 
Oxytetracycline 4 8 Susceptible 
Streptomycin 8 8 Susceptible 
Vancomycin 1 4 Susceptible 
1 n.r. not required 
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The strain was susceptible to all antibiotics tested, as the minimum inhibitory 
concentrations were lower or the same as the EFSA breakpoint. Since interest in B. 
coagulans and other Bacillus species as probiotics is fairly recent, there is little available 
published information on antibiotic susceptibility profiles. Sorokulova et al. (92) studied 
a B. subtilis and a B. licheniformis strain for antibiotic resistance; while the former was 
sensitive to all antibiotics listed by EFSA the latter was resistant to chloramphenicol and 
clindamycin. Hong et al. (93) found no antibiotic resistance in a B. subtilis strain and 
clindamycin resistance in a B. indicus strain. Clindamycin resistance appears to be a 
concern in probiotic Bacillus strains. The strain studied here, however, shows no 
resistance and can be classified as safe for use as a probiotic. 
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CHAPTER 4 : CONCLUSIONS AND FUTURE RESEARCH 
  
60 
 
4.1 Conclusions 
• The prebiotic utilization profile of ten probiotic strains was determined.  
o Lactobacillus acidophilus, Lb. brevis and Lb. delbrueckii subsp. 
bulgaricus were unable to ferment any of the four prebiotics tested.  
o Orafti P95 FOS and Orafti Synergy 1 inulin did not support growth of any 
of the strains tested.  
o Purimune galactooligosaccharide (GOS) was fermented by Lb. casei, Lb. 
plantarum, Lb. rhamnosus, Lb. salivarius, Lactococcus lactis, 
Bifidobacterium longum and Bacillus coagulans.  
o Nutraflora P95 fructooligosaccharide (FOS) was fermented by Lb. 
plantarum and Lb. salivarius. These prebiotic-probiotic combinations 
could be used for a synbiotic formulation. 
• The susceptibility of ten probiotic strains to nine antibiotics was evaluated by two 
methods.  
o Only Lb. salivarius showed resistance to three antibiotics: gentamycin, 
kanamycin and streptomycin; and should not be considered safe for 
probiotic use. 
o The antibiotic susceptibility profiles obtained by the broth microdilution 
method and the disk diffusion method were in agreement for 76.8% 
(63/82) of the possible strain-antibiotic combinations, which is considered 
satisfactory. They also had acceptable repeatability. 
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• B. coagulans was able to survive acid and bile conditions in vitro for up to 4 
hours with a 1.0 log reduction in bile salts and a 2.0 log reduction in pH 2.0. This 
predicts survival of the passage through the intestinal tract and success as a 
probiotic. 
 
4.2 Future Research 
Areas of interest to continue with this research include: 
• In vivo evaluation of prebiotic utilization by the probiotic strains and possible 
synbiotic effects. 
• Anaerobic evaluation of prebiotic utilization by Lactobacillus acidophilus. 
• Determination of resistance determinants in Lactobacillus salivarius and strains 
found to be resistant in just one of the two methods tested. 
• Examination of a larger set of strains by both microdilution and disk diffusion 
methods in order to establish updated evaluation criteria for the disk diffusion 
method. 
• Determination of acid and bile resistance of B. coagulans in vivo or in vitro by a 
more complex model. 
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